a second group of 20 women received a placebo
The patients were diagnosed using the WHO criteria of post-COVID (long COVID) [52], namely: (a) individuals having a history of proven SARS-CoV-2 infection, (b) symptoms persisted beyond the acute phase of illness or manifested during recovery from acute COVID-19 infection, (c) symptoms lasted at least 2 months and are present 34 months after the onset of COVID-19, and (d) patients suffer from at least two symptoms that impair daily functioning including fatigue, memory or concentration problems, shortness of breath, chest pain, persistent cough, difficulty speaking, muscle aches, loss of smell or taste, affective symptoms, cognitive impairment, or fever [52]
The potential of hydrogen for improving mental disorders
BPC 157 Australia is one of the most in-demand supplements for advanced recovery and healing
Targeting NAD(+) degradation: the therapeutic potential of flavonoids for Alzheimers disease and cognitive frailty
Harder to self-administer but viable